Termination of synaptic
glutamate transmission depends on rapid removal of
glutamate by neuronal and glial high-affinity transporters. Molecular
biological and pharmacological studies have demonstrated that at least five subtypes of Na+-dependent mammalian
glutamate transporters exist. Our study demonstrates that Y-79 human
retinoblastoma cells express a single Na+-dependent
glutamate uptake system with a Km of 1.7 +/- 0.42 microM that is inhibited by
dihydrokainate and DL-threo-beta-hydroxyaspartate (IC50 = 0.29 +/- 0.17 microM and 2.0 +/- 0.43 microM, respectively). The
protein kinase C activator
phorbol 12-myristate 13-acetate caused a concentration-dependent inhibition of
glutamate uptake (IC50 = 0.56 +/- 0.05 nM), but did not affect Na+-dependent
glycine uptake significantly. This inhibition of
glutamate uptake resulted from a fivefold decrease in the transporter's affinity for
glutamate, without significantly altering the Vmax.
4Alpha-phorbol 12,13-didecanoate, a
phorbol ester that does not activate
protein kinase C, did not alter
glutamate uptake significantly. The
phorbol 12-myristate 13-acetate-induced inhibition of
glutamate uptake was reversed by preincubation with
staurosporine. The biophysical and pharmacological profile of the human
glutamate transporter expressed by the Y-79 cell line indicates that it belongs to the
dihydrokainate-sensitive EAAT2/GLT-1 subtype. This conclusion was confirmed by western blot analysis.
Protein kinase C modulation of
glutamate transporter activity may represent a mechanism to modulate extracellular
glutamate and shape postsynaptic responses.